RELA

Pre-Launch

carisoprodol

NDAORALTABLET
Lifecycle
Pre-Launch
Clinical Trials
20

Clinical Trials (5)

NCT05462639N/ANo Longer Available

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma
NCT02568943N/ANo Longer Available

An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma

Multiple Myeloma
NCT03409081N/ANo Longer Available

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations
NCT00002131Phase 2Completed

A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma

28 enrolled
Sarcoma, KaposiHIV Infections
NCT04559555N/ANo Longer Available

MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia (ALL)